ArticleNeuropsychiatric disease and treatment2026
Real-World Antidepressant Treatment Persistence in Children and Adolescents with Major Depressive Disorder in Japan: A Retrospective Nationwide Claims-Based Study.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Real-world evidence on major depressive disorder (MDD) management in children and adolescents is limited in Japan. This study aimed to evaluate the antidepressant treatment persistence rate in this population. Patients and Methods: This study evaluated the antidepressant treatment persistence in children and adolescents (aged 6-18 years) with MDD who had claims data from 6 months before to 1 year after the index date between 2012 and 2017 using a large-scale Japanese claims database. Treatment persistence was defined as the absence of a prescription gap beyond 30 days. Factors associated with it were examined using a Cox proportional hazards model (JMP ver.18). Results: In total, 1,582 patients on the index date were included. The treatment persistence rate for any antidepressant was 62.6% on the 30th postindex day, 46.1% on the 60th postindex day, 22.3% on the 180th postindex day, and 10.2% on the 365th postindex day. The most frequently prescribed initial antidepressant was sulpiride (30.0%). By drug class, selective serotonin reuptake inhibitors (SSRIs) were the most frequently prescribed (39.9%), followed by tricyclic or tetracyclic antidepressants (TCAs) (18.3%) and serotonin and norepinephrine reuptake inhibitors (SNRIs) (6.3%). The significant factors associated with treatment discontinuation with any antidepressant were treatment initiation with sulpiride, noradrenergic and specific serotonergic antidepressants, serotonin antagonist and reuptake inhibitors, or TCAs, as well as consultations with nonmental health specialists. Conclusion: Antidepressant treatment persistence rates in children and adolescents with MDD were low. However, the rate varied depending on the first prescribed antidepressant and mental health specialist involvement. Relatively high persistence was observed among those prescribed SSRIs or SNRIs as their initial antidepressant treatment and those who received clinical interventions provided by mental health specialists. Given the claims data and no clinical severity measures, these findings should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.